Nasal flu vaccine, FluMist, approved for next flu season

Nasal flu vaccine, FluMist, approved for next flu season

21, the US Centers for Disease Control's Advisory Committee on Immunization Practices (ACIP) voted 12-2 to once again endorse FluMist, a vaccine for the flu that can be inhaled like an allergy medicine, for the 2018-2019 season.

Several South Jersey parents were upset two years ago when the nasal spray was no longer offered by most pediatricians, saying it was easier on their children to get the nasal spray than a shot.

The recommendation was based on new data which showed that the 2017-2018 H1N1 LAIV post-pandemic strain performed significantly better than the 2015-2016 strain.

Next flu season you'll be able to get your vaccine without a needle.

While the vote clears the way for FluMist to re-enter the US market as a more widely used option, it may be too late for the vaccine to play a major role in next winter's flu season. It's the only nasal spray flu vaccine on the market and is approved for people aged 2 to 49.

This flu season has been one of the deadliest in recent memory.

Sources Say More Amazon Go Stores to Open in Seattle, LA
The Seattle Amazon Go store mostly sells fresh food items, including the company's exclusive meal kits . Amazon's much-heralded convenience store of the future, Amazon Go, may seem like a insane experiment.

The difference in the vaccines' effectiveness was due to their makeup: FluMist was a live but weakened influenza vaccine, while the flu shot contains a dead virus.

The vaccine will still be subject to annual strain approval by the FDA for next season.

A third child in New Jersey has died from a confirmed case of the flu, state officials said, as the death rate continues to climb nationally.

FluMist will be available in the USA for the 2018-2019 influenza season, pending annual strain approval from the FDA.

This wording puts FluMist on the "recommended" list, which means insurance companies have to pay for its use, without being a strong endorsement.

"There is potential for harm if the new formulation of (FluMist) is recommended and used and is not effective", the CDC's Dr. Lisa Grohskopf, who is not a member of ACIP and who led a team reviewing FluMist's past effectiveness, told the committee.

Related Articles